Depression in diabetes: Evidencebased treatment

Studies have demonstrated that people with diabetes who have comorbid depression often have poor glycaemic control, and are at increased risk of developing diabetes-related complications. In this article, the authors undertook a literature review to investigate depression treatments in this population to assist primary healthcare professionals in making informed decisions regarding effective antidepressant therapy. Current evidence suggests that selective serotonin reuptake inhibitors, particularly sertraline, offer a significant therapeutic advantage for people with diabetes with comorbid depression over tricyclic antidepressants or monoamine oxidase inhibitors.